6:46 PM
 | 
Nov 04, 2014
 |  BC Extra  |  Company News

After BMS deal, F-star launches second newco

F-star Biotechnology Ltd. (Cambridge, U.K.) launched newco F-star Beta Ltd. (Cambridge, U.K.) and granted it licenses to develop antibody fragments and bispecific antibodies against certain oncology and immuno-oncology targets. F-star Biotechnology is eligible for milestones and tiered royalties. Specific terms are undisclosed.

F-star Beta is the second asset-centric company F-star Biotechnology has...

Read the full 242 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >